Sp1176
HOW TO DELIVER AFFIRMING CARE FOR SEXUAL AND GENDER MINORITY PATIENTS IN THE WORLD OF DIGESTIVE DISORDERS
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
LGBTQ+ health care providers and patients are a growing and visible part of GI and liver practice. This session spotlights clinicians who are addressing the health needs for the LGBTQ+ population of patients, providers and learners. Two of the sessions will provide vital clinical updates for all clinicians on anorectal disease and provider affirming care for the transgender community. Two other sessions will share strategies for creating a safe and effective practice and learning environment for sexual and gender minority patients, providers and learners. Practice and divisional leaders as well as clinicians will benefit from this session.
LGBTQ+ health care providers and patients are a growing and visible part of GI and liver practice. This session spotlights clinicians who are addressing the health needs for the LGBTQ+ population of patients, providers and learners. Two of the sessions will provide vital clinical updates for all clinicians on anorectal disease and provider affirming care for the transgender community. Two other sessions will share strategies for creating a safe and effective practice and learning environment for sexual and gender minority patients, providers and learners. Practice and divisional leaders as well as clinicians will benefit from this session.
Presenter
Massachusetts General Hospital
Tracks
Related Products
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PANEL DISCUSSION
LGBTQ+ health care providers and patients are a growing and visible part of GI and liver practice. This session spotlights clinicians who are addressing the health needs for the LGBTQ+ population of patients, providers and learners…
